Sutro Biopharma, Inc. Files DEF 14A with Executive Compensation Details

TL;DR

<b>Sutro Biopharma's DEF 14A filing provides detailed executive compensation information for 2021-2023.</b>

AI Summary

SUTRO BIOPHARMA, INC. (STRO) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Sutro Biopharma, Inc. (STRO) filed a DEF 14A on April 26, 2024, for the period ending June 6, 2024. The filing details executive compensation, including changes in fair value of stock and option awards for PEO and Non-PEO members. Specific dates for award vesting and grant dates are referenced for the years 2021, 2022, and 2023. The company's principal executive offices are located at 111 Oyster Point Blvd., South San Francisco, CA 94080. The filing includes information on the fair value of unvested stock and option awards granted in prior years.

Why It Matters

For investors and stakeholders tracking SUTRO BIOPHARMA, INC., this filing contains several important signals. This filing is crucial for shareholders to understand how executive compensation is structured and how it relates to the company's performance and stock valuation. Understanding the changes in fair value of stock and option awards can provide insights into management's incentives and the perceived value of the company's equity.

Risk Assessment

Risk Level: low — SUTRO BIOPHARMA, INC. shows low risk based on this filing. The filing is a routine disclosure of executive compensation and does not contain new operational or financial performance data, thus posing a low risk.

Analyst Insight

Review the executive compensation details to assess alignment with company performance and shareholder interests.

Key Numbers

• 2021-01-01 — Award Grant/Vesting Period Start (Fair value of stock and option awards)
• 2023-12-31 — Award Grant/Vesting Period End (Fair value of stock and option awards)
• 2022 — Fiscal Year (Change in fair value of stock and option awards)
• 2023 — Fiscal Year (Change in fair value of stock and option awards)

Key Players & Entities

• SUTRO BIOPHARMA, INC. (company) — COMPANY CONFORMED NAME
• STRO (company) — Ticker Symbol
• DEF 14A (document) — FORM TYPE
• 2024-04-26 (date) — FILED AS OF DATE
• 2024-06-06 (date) — CONFORMED PERIOD OF REPORT
• 111 OYSTER POINT BLVD. (address) — BUSINESS ADDRESS STREET 1
• SOUTH SAN FRANCISCO (location) — BUSINESS ADDRESS CITY
• CA (location) — BUSINESS ADDRESS STATE

FAQ

Industry Context

Sutro Biopharma operates in the biotechnology sector, focusing on the development of novel protein-engineered therapeutics.

Regulatory Implications

The DEF 14A filing is a regulatory requirement under the Securities Exchange Act of 1934, mandating disclosure of information regarding executive compensation and corporate governance.

What Investors Should Do

1. Analyze the specific components of executive compensation, including base salary, bonuses, stock awards, and option awards.
2. Compare the reported compensation figures with industry benchmarks and the company's financial performance.
3. Evaluate the rationale provided for any significant changes in executive compensation from prior periods.

Key Dates

• 2024-04-26: Filing Date — DEF 14A filing submitted.
• 2024-06-06: Reporting Period End — Period for which the filing is relevant.

Year-Over-Year Comparison

This filing is a DEF 14A, which is a proxy statement providing details on executive compensation and annual meeting matters, distinct from financial performance reports like 10-K or 10-Q.

Filing Documents

• stro-20240425.htm (DEF 14A) — 1185KB
• img142447830_0.jpg (GRAPHIC) — 6KB
• img142447830_1.jpg (GRAPHIC) — 26KB
• img142447830_2.jpg (GRAPHIC) — 24KB
• img142447830_3.jpg (GRAPHIC) — 80KB
• img142447830_4.jpg (GRAPHIC) — 61KB
• 0000950170-24-049207.txt (&nbsp;) — 2192KB
• stro-20240425.xsd (EX-101.SCH) — 24KB
• stro-20240425_htm.xml (XML) — 111KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 19 EXECUTIVE OFFICERS 22

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 23 PAY VERSUS PERFORMANCE 38 EQUITY COMPENSATION PLAN INFORMATION 40 PROPOSAL NO. 3 NON-BINDING ADVISORY VOTE ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS 41 PROPOSAL NO. 4 AMENDMENT TO OUR 2018 EMPLOYEE STOCK PURCHASE PLAN 42 CERTAIN RELATIONSHIPS AND RELATED-PARTY TRANSACTIONS 46 ADDITIONAL INFORMATION 47 OTHER MATTERS 48 APPENDIX A 49 SUTRO BIOPHARMA, INC. 111 Oyster Point Boulevard South San Francisco, California, 94080 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS April 26, 2024 INFORMATION ABOUT SOL ICITATION AND VOTING The accompanying proxy is solicited on behalf of the Board of Directors of Sutro Biopharma, Inc. (Sutro Biopharma or the Company) for use at Sutro Biopharma's 2024 Annual Meeting of Stockholders (Annual Meeting) to be held via a virtual meeting. You will be able to participate in the Annual Meeting and vote during the Annual Meeting via live webcast by visiting www.virtualshareholdermeeting.com/STRO2024 on Thursday, June 6, 2024 at 9:00 AM Pacific Time and any adjournment or postponement thereof. We believe that a virtual stockholder meeting provides greater access to those who may want to attend, and therefore we have chosen this format over an in-person meeting. This approach also lowers costs and aligns with our broader sustainability goals. You will need the control number included on your proxy card or voting instruction form, or included in the e-mail to you if you received the proxy materials by e-mail, as such number will be required in order for stockholders to gain access to the virtual meeting. We are making this proxy statement, the accompanying form of proxy and our Annual Report on Form 10K for the year ended December 31, 2023 first available to stockholders on or about April 26, 2024. An electronic copy of this proxy statement and Annual Report on Form 10K are available at http://ir.sutrobio.com . INTERNET AVAILABILITY OF PROXY MATERIALS

View Full Filing

View this DEF 14A filing on SEC EDGAR